1.8000 -0.01 (-0.55%)
Pre-Market: 8:04AM EDT
|Bid||1.8000 x 800|
|Ask||2.0400 x 800|
|Day's Range||1.7900 - 1.8670|
|52 Week Range||1.3500 - 3.0900|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.67|
Athersys, Inc. (ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the longest running, large-scale conference in the world offering groundbreaking research in pulmonary, critical care and sleep medicine.
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
CLEVELAND, May 08, 2019 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern Time. ...
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Athersys, Inc. (ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory distress syndrome (“ARDS”). The clinical trial investigates the efficacy and safety of MultiStem therapy for patients with pneumonia-induced ARDS.
Athersys, Inc. (ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical Director at the Eddy Scurlock Stroke Center at Houston Methodist Hospital will be discussing the MASTERS-2 clinical trial for stroke.
CLEVELAND, April 10, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8,.
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Substantial progress over the year, advancing programs andexpanding collaboration with HEALIOS K.K. Management to host conference call at 4:30 PM EST today CLEVELAND, March.
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Gil Van Bokkelen has been the CEO of Athersys, Inc. (NASDAQ:ATHX) since 1995. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look atRead More...
CLEVELAND, Feb. 14, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019,.
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys, Inc. (ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment. Importantly, MultiStem treatment was associated with lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo.
Athersys, Inc. (ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization of MultiStem therapy for certain indications in China. Healios has agreed to make a one-time $2.0 million payment in December 2018 for an extension through June 30, 2019. Furthermore, Healios may make an additional payment of $3.0 million to extend the negotiation period for another six months through December 31, 2019.